ABIVAX: ABX464 hits the bar in phase IIb and is now phase III-ready in UC | BUY TOP PICKS | EUR48 VS. 39
ABIVAX - BUY TOP PICKS | EUR48 VS. 39(+120%)ABX464 hits the bar in phase IIb and is now phase III-ready in UC
ABX464 meets the primary endpoint of its phase IIb trial in UC
All of the efficacy endpoints going into the right direction
Unexpected strong results with the 25 mg dose
First positive signs in the maintenance phase
Increase in our TP
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.